Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sirtris Pharmaceuticals has announced that its oral drug candidate was shown to be neuroprotective in an animal model of optic neuritis characterized by inflammation of the optic nerve that can cause a complete or partial loss of vision.
Subscribe to our email newsletter
A poster, titled ‘Neuroprotection in CNS demyelinating disease by SIRT1 activators, a potential oral therapy’ presented at the annual meeting of the american neurological association, showed that oral dosing of SRT501, a proprietary formulation of resveratrol, reduced the loss of retinal ganglion cells and preserved axonal function in a preclinical model of optic neuritis.
Peter Elliott, senior vice president of development at Sirtris, said: “This is the first time that an orally administered SIRT1 activator has demonstrated neuroprotection; these are encouraging data and further support the potential for SRT501 as a therapeutic for a range of neurodegenerative diseases of aging.”
Christoph Westphal, CEO of Sirtris, said: “These new findings add to a growing body of data that demonstrate that SIRT1 is an important therapeutic target for a broad range of diseases of aging, including metabolic, mitochondrial and neurological disorders.”